GPT-6 Astra, .name termination, and OpenAI, Claude, Grok outages
First things first
A lot is happening in AI, with new models launching and big companies making moves. There’s also some chaos with outages and security issues, plus debates about digital ownership and privacy.
It’s a wild mix of tech advances, industry shifts, and a dash of weird human stories that make you go hmm. Just another day in the fast-paced world of tech and internet stuff.
The top 6
.name Termination
Verisign plans to terminate the entire .name third-level domain hierarchy to simplify management, affecting nearly 22,000 users including Neil Fraser. This will result in the loss of websites, emails, and IoT services tied to these domains, raising concerns about domain hijacking and account security.
Ask HN: Why are OpenAI, Claude, and Grok simultaneously down? Coincidence?
Any Human Ever – One life, drawn at random from all who have ever lived
Qwen 3.8 27B available on Cerebras at 1500 tok/SEC
ChatGPT Is Throwing 404
Support our sponsor
Your Newsletter Deserves Better Than a Free Plan
Quote of the day
Vision is the art of seeing what is invisible to others.
Jonathan Swift
Also big today
Mom Gets 6-Mo Suspended Sentence for Letting 5-Year-Old Walk to the Pond
Karyann Parkinson was sentenced to a six-month suspended jail term and placed on the child abuse registry after allowing her 5-year-old son to walk alone in their community. Authorities investigated her for neglect after a passerby saw the child, leading to legal charges despite her safety precautions.
OpenAI begins rolling out Astra model after warning advanced cyber capabilities
New York Times and The Athletic workers demand company scrap Kalshi deal
Sony makes bold claim about game ownership
Nvidia to Acquire Hugging Face
K2 Horizon: Frontier Performance, Radically Open
K2 Horizon is a fleet of six open-source models ranging from 0.9B to 375B parameters, achieving state-of-the-art performance across various tasks. The release includes complete training data, code, and logs, enabling researchers to study and reproduce the development of reasoning and agentic capabilities.
Pass it on
Enjoying the digest?
Forward it to someone who'd like it, or send them the link to subscribe.
Share hn.todayOne for the road
Today, at the bank, an old lady asked me to check her balance.
So I pushed her over.
Worth a look
Porting my 1993 Amiga game to Godot, with an LLM reading the 68000 assembly
Elevated Errors for Multiple Models
Artificial beaver dams saw juvenile coho salmon survival rates go from 8% to 60%
OpenAI's GPT-6 Astra on ARC-AGI-3
The asteroid currently hitting front end web development
Which tools do Claude, Codex and Cursor choose? We measured 17k runs to find out
Researchers analyzed nearly 17,000 sessions to see which tools coding agents like Claude Code, Codex, and Cursor prefer for various tasks. The study found consistent tool choices across different personas and codebases, highlighting trends in how these agents select and implement tools in development workflows.
Song of the day
Deep cuts
Grok Outage
Hackers Had a Live Feed of Every ID Verification Company Scanned for over a Year
How concerned should we be about Astra's recurrent architecture?
120 days until Google restricts side-loading, declaring war on Android freedom
VC isn't VC anymore – understanding the rise of Cancer Capital
Venture capital has shifted from supporting innovation to being controlled by a small group of billionaires with little accountability, creating an oligarchic influence on society. This transformation, termed 'Cancer Capital,' has amplified societal and political issues by warping the original purpose of VC as a limited funding source for startups.
GLP-1s Are Being Linked to Fewer Serious Infections, Including TB
Recent studies suggest that GLP-1 drugs like Ozempic and tirzepatide may reduce the risk of serious infections such as tuberculosis and bacterial infections. These findings indicate potential additional benefits of GLP-1 medications beyond their metabolic effects, especially for vulnerable groups like people with type 2 diabetes.